Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLUE bluebird bio	$4.97	$4.78	$3.20 ▼ $28.60	$48.67M	0.27	447,349 shs	N/A
CTMX CytomX Therapeutics	$2.43 +1.2%	$2.29	$0.40 ▼ $3.10	$196.31M	2.05	2.20 million shs	78,397 shs
SXTC China SXT Pharmaceuticals	$1.70 +1.6%	$1.72	$0.95 ▼ $10.24	$196.90M	1.18	2.14 million shs	1,632 shs
VYGR Voyager Therapeutics	$3.28 +6.3%	$3.19	$2.65 ▼ $9.55	$181.17M	0.85	487,437 shs	121,435 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLUE bluebird bio	0.00%	0.00%	0.00%	+19.76%	-81.17%
CTMX CytomX Therapeutics	+0.42%	0.00%	-12.73%	+281.13%	+70.21%
SXTC China SXT Pharmaceuticals	+0.48%	-5.76%	-8.85%	+68.67%	-82.33%
VYGR Voyager Therapeutics	-10.20%	-3.14%	-6.67%	-1.60%	-65.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLUE bluebird bio	1.5733 of 5 stars	3.1	0.0	0.0	0.0	1.7	1.3
CTMX CytomX Therapeutics	4.1417 of 5 stars	3.5	1.0	4.7	2.4	1.7	1.3
SXTC China SXT Pharmaceuticals	0.9304 of 5 stars	0.0	5.0	0.0	2.2	0.0	0.6
VYGR Voyager Therapeutics	3.8932 of 5 stars	3.6	2.0	4.6	1.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLUE bluebird bio	2.25	Hold	$44.60	797.38% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	119.66% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
VYGR Voyager Therapeutics	3.13	Buy	$13.39	308.85% Upside

Current Analyst Ratings Breakdown

Latest BLUE, CTMX, SXTC, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CTMX CytomX Therapeutics	$147.56M	1.33	$0.37 per share	6.60	($0.01) per share	-242.80
SXTC China SXT Pharmaceuticals	$1.82M	108.15	N/A	N/A	$243.66 per share	0.01
VYGR Voyager Therapeutics	$66.96M	2.71	N/A	N/A	$5.49 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	8/12/2025 (Estimated)
CTMX CytomX Therapeutics	$31.87M	$0.48	5.07	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	-$65M	-$1.46	N/A	N/A	N/A	-126.49%	-27.36%	-21.06%	8/5/2025 (Estimated)

Latest BLUE, CTMX, SXTC, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q1 2025	BLUE bluebird bio	-$1.91	N/A	N/A	N/A	$45.60 million	N/A
8/5/2025	Q2 2025	VYGR Voyager Therapeutics	-$0.48	N/A	N/A	N/A	$9.50 million	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/6/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	-$0.53	-$0.18	-$0.53	$13.55 million	$6.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLUE bluebird bio	0.37	0.51	0.33
CTMX CytomX Therapeutics	N/A	1.73	1.73
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	6.10	6.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLUE bluebird bio	87.43%
CTMX CytomX Therapeutics	67.77%
SXTC China SXT Pharmaceuticals	5.02%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
BLUE bluebird bio	1.40%
CTMX CytomX Therapeutics	6.60%
SXTC China SXT Pharmaceuticals	3.95%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
VYGR Voyager Therapeutics	100	55.34 million	52.83 million	Optionable

BLUE, CTMX, SXTC, and VYGR Headlines

Recent News About These Companies

Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

4 hours ago | globenewswire.com

Moon + Bird acquires Alastair Chisholm's book about NASA’s Voyager 1

July 15 at 2:13 PM | thebookseller.comT

Embark On a Summer Adventure Abroad Star Voyager Cruise to Naha, Sanya and More

July 14 at 7:50 PM | prestigeonline.comP

Voyager’s Tim Russ Doesn’t Think a Black Vulcan Is a Feat for Star Trek

July 14 at 7:50 PM | fandomwire.comF

UK awards AirTanker network node upgrade for Voyager

July 11, 2025 | janes.comJ

Voyager 1 & 2 Could Be Detected From Almost A Light-Year Away With Our Current Technology

July 10, 2025 | msn.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $13.39

July 8, 2025 | americanbankingnews.com

RNLI thanks Condor Voyager for helping save French yacht crew in 'challenging conditions'

July 7, 2025 | itv.comI

Atlas Announces New Canadian Arctic Expedition Aboard World Voyager

July 6, 2025 | cruiseindustrynews.comC

With Alipay+ Voyager, Ant International provides an AI travel assistant in Asian E-Wallets

July 5, 2025 | travelmole.comT

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from Brokerages

July 5, 2025 | marketbeat.com

Ant International launches Alipay+ Voyager, an AI-powered travel assistant inside e-wallets

July 3, 2025 | walastech.comW

VYGR Voyager Therapeutics, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

Major Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With Paint

June 20, 2025 | theaviationist.comT

Protesters Vandalize RAF Voyager Tankers In Palestine Protest

June 20, 2025 | aviationweek.comA

Voyager Technologies Soars with IPO Success

June 14, 2025 | devdiscourse.comD

Space Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss Expansion

June 12, 2025 | devdiscourse.comD

Voyager Technologies Rises in Debut, Signaling Improving IPO Market

June 12, 2025 | msn.com

Voyager soars 82% on first day of trading as defense tech booms

June 12, 2025 | msn.com

Investor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOs

June 11, 2025 | msn.com

Voyager Technologies' Shares More Than Double in NYSE Debut

June 11, 2025 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
By Chris Markoch | July 8, 2025
View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
5 High-Yielding ETFs to Buy and Hold Forever
By Ryan Hasson | June 30, 2025
View 5 High-Yielding ETFs to Buy and Hold Forever

BLUE, CTMX, SXTC, and VYGR Company Descriptions

bluebird bio NASDAQ:BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CytomX Therapeutics NASDAQ:CTMX

$2.43 +0.03 (+1.17%)

As of 10:25 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.70 +0.03 (+1.62%)

As of 10:24 AM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.20 (+6.33%)

As of 10:25 AM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time